Connect your AI

Vaxcyte, Inc. PCVX Other contractual commitments, Due in 2026 (remainder)

Other financials

Income statement

Operating income-$345.9M-91.3%

Net income-$320.6M-128%

EPS (diluted)-$2.30-121%

Balance sheet

Cash & equivalents$262.3M-24.7%

Total debt$116.3M+33.5%

Total equity$3.0B-6.4%

Total assets$3.3B-0.9%

Cash flow

Operating cash flow-$280.6M-68.8%

CapEx$2.1M-61.2%

Free cash flow-$282.7M-64.7%

Valuation

Market cap$7.43B+72.0%

Enterprise value$7.28B+78.6%

Returns & leverage

Return on equity-30.6%+37.9pp

Debt / equity0×0.0×

Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear.

The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vaxcyte, Inc.'s other contractual commitments, due in 2026 (remainder).

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Vaxcyte, Inc.'s other contractual commitments, due in 2026 (remainder)?: Vaxcyte, Inc. (PCVX) reported other contractual commitments, due in 2026 (remainder) of $512.54M in Q1 2026.
How has Vaxcyte, Inc.'s other contractual commitments, due in 2026 (remainder) changed year-over-year?: Vaxcyte, Inc.'s other contractual commitments, due in 2026 (remainder) increased by 93.3% year-over-year, from $265.22M to $512.54M.